An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.

Trial Profile

An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors UCB
  • Most Recent Events

    • 08 Jun 2017 Results of post hoc analysis of pooled data from 6 placebo contolled trials (SP506, SP512, SP513, SP515, SP650, and SP921) presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 18 Jun 2015 Post hoc pooled analysis (SP702, SP716 and preceding double-blind trials) of 6-month earlier treatment initiation on long-term outcome; results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 20 Apr 2015 Post-hoc analysis of pooled data presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), according to a UCB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top